Overview of Изосорбида мононитрат
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Isosorbide Mononitrate |
| Form | Tablets (immediate- and extended-release) |
| Pharmacological class | Organic Nitrates, Vasodilators |
| General purpose | Prophylaxis of Angina Pectoris |
| Origin | Synthetic |
Что такое Изосорбида мононитрат и к какому классу относится?
Изосорбида мононитрат (Isosorbide Mononitrate) is a synthetic chemical compound classified as an organic nitrate, functioning as a powerful vasodilator. The active substance, Isosorbide-5-mononitrate, is a stable glucitol derivative that is inherently active in the body, meaning it readily exerts its effect without requiring the extensive prior metabolic conversion necessary for some related medicines. This intrinsic activity is clinically recognized for providing high and consistent oral bioavailability, making it well-suited for reliable long-term therapeutic use. The agent is available only by prescription and is recognized as a key antianginal agent within its therapeutic class.
Принцип действия и основное назначение
The core principle of action for Isosorbide Mononitrate is the promotion of widespread vasodilation, which occurs when the medicine releases Nitric Oxide into the circulatory system. This mechanism causes the smooth muscles in the walls of blood vessels to relax, primarily affecting the large veins. By causing a significant reduction in the volume of blood returning to the heart—a process termed decreased cardiac preload—the medication effectively lessens the overall workload on the heart muscle. The established clinical purpose of the drug is the prophylaxis (prevention) of chronic episodes of heart-related chest discomfort, or angina pectoris, ensuring a continuous balance between the heart's oxygen supply and demand, a scenario frequently seen in patients with coronary artery disease.
Основные фармацевтические формы
The drug is designed for oral administration and is supplied as tablets, formulated to contain a single active ingredient. Key pharmaceutical forms include both immediate-release and extended-release tablets. The extended-release system, which offers sustained action, is particularly noted for its design, aiming to provide consistent, stable therapeutic levels over a prolonged period. This feature is essential for supporting patient adherence and effective long-term management of chronic cardiovascular conditions.

